Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.

Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ.

Mol Cancer Res. 2010 May;8(5):729-38. doi: 10.1158/1541-7786.MCR-10-0022. Epub 2010 May 4.

2.

Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.

Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, Kusukawa J, Kage M, Shirouzu K, Yamana H.

Mol Cancer Ther. 2010 Jun;9(6):1842-51. doi: 10.1158/1535-7163.MCT-09-0918. Epub 2010 Jun 1.

3.

Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.

Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ.

J Natl Cancer Inst. 2008 May 7;100(9):649-62. doi: 10.1093/jnci/djn113. Epub 2008 Apr 29.

4.

Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.

Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R.

Mol Cancer Ther. 2009 Feb;8(2):292-302. doi: 10.1158/1535-7163.MCT-08-0918. Epub 2009 Jan 27.

5.

Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.

Bullenkamp J, Raulf N, Ayaz B, Walczak H, Kulms D, Odell E, Thavaraj S, Tavassoli M.

Cell Death Dis. 2014 Oct 23;5:e1489. doi: 10.1038/cddis.2014.455.

6.

Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.

Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S.

Clin Cancer Res. 2011 Jun 15;17(12):4019-30. doi: 10.1158/1078-0432.CCR-11-0075. Epub 2011 Apr 27.

7.

Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage.

Ramp U, Caliskan E, Mahotka C, Krieg A, Heikaus S, Gabbert HE, Gerharz CD.

Br J Cancer. 2003 Jun 2;88(11):1800-7.

8.

TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.

Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA.

Mol Cancer Ther. 2007 Jul;6(7):2103-12.

9.
10.

Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.

Laussmann MA, Passante E, Hellwig CT, Tomiczek B, Flanagan L, Prehn JH, Huber HJ, Rehm M.

J Biol Chem. 2012 Apr 27;287(18):14402-11. doi: 10.1074/jbc.M111.304378. Epub 2012 Mar 9.

11.

Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.

Jane EP, Premkumar DR, Pollack IF.

Mol Cancer Ther. 2011 Jan;10(1):198-208. doi: 10.1158/1535-7163.MCT-10-0725.

13.

Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.

Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR, Altieri DC, Sandler AD.

Cancer Res. 2002 Jun 1;62(11):3093-9.

14.

Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.

Balsas P, López-Royuela N, Galán-Malo P, Anel A, Marzo I, Naval J.

Biochem Pharmacol. 2009 Mar 1;77(5):804-12. doi: 10.1016/j.bcp.2008.11.024. Epub 2008 Dec 3.

PMID:
19100720
15.

Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.

Koschny R, Boehm C, Sprick MR, Haas TL, Holland H, Xu LX, Krupp W, Mueller WC, Bauer M, Koschny T, Keller M, Sinn P, Meixensberger J, Walczak H, Ganten TM.

J Neuropathol Exp Neurol. 2014 Nov;73(11):1034-46. doi: 10.1097/NEN.0000000000000129.

16.

The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.

Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB.

Apoptosis. 2006 Jul;11(7):1175-93.

PMID:
16699949
17.

Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.

Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B.

J Immunol. 2008 May 1;180(9):6199-210.

18.

The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.

Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS.

Mol Cancer Ther. 2005 Mar;4(3):443-9.

19.

The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.

Brooks AD, Ramirez T, Toh U, Onksen J, Elliott PJ, Murphy WJ, Sayers TJ.

Ann N Y Acad Sci. 2005 Nov;1059:160-7.

PMID:
16382051
20.

Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.

Bychkov ML, Gasparian ME, Dolgikh DA, Kirpichnikov MP.

PLoS One. 2014 Oct 13;9(10):e109756. doi: 10.1371/journal.pone.0109756. eCollection 2014.

Items per page

Supplemental Content

Write to the Help Desk